{"id":277658,"date":"2026-09-29T12:25:13","date_gmt":"2026-09-29T06:55:13","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=277658"},"modified":"2026-09-29T12:25:13","modified_gmt":"2026-09-29T06:55:13","slug":"jagsnpharm-best-stock-in-its-sector","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/jagsnpharm-best-stock-in-its-sector\/","title":{"rendered":"Is Jagsonpal Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers"},"content":{"rendered":"

Jagsonpal Pharmaceuticals CMP Rs 236 (29 Sep 2026). Market cap Rs 1,586 Cr. ROE 15.60%. P\/E 34.89x versus Industry P\/E 51.67x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Jagsonpal Pharmaceuticals is one of the names investors compare when screening the Healthcare sector, built on a 15.60% return on equity and a P\/E of 34.89x against an Industry P\/E of 51.67x. Whether Jagsonpal Pharmaceuticals is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.<\/p>\n<\/p><\/div>\n

Is Jagsonpal Pharmaceuticals<\/a> the best stock in its sector? The stock trades on the NSE at Rs 236 as of 29 September 2026, within its 52-week range of Rs 155.00 to Rs 264.50. Jagsonpal Pharmaceuticals Ltd manufactures and markets branded pharmaceutical formulations.<\/p>\n

Jagsonpal Pharmaceuticals sits in the Healthcare sector, and its 15.60% ROE and 34.89x P\/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P\/E benchmark.<\/p>\n

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers<\/a><\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n